Q4 2024 Earnings Call Transcript March 20, 2025 Monte Rosa Therapeutics, Inc. beats earnings expectations. Reported EPS is $0 ...

Monte Rosa Therapeutics, Inc.’s GLUE share price has dipped by 17.85%, which has investors questioning if this is right time ...

Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report)‘s stock had its “outperform” rating reaffirmed by investment analysts at Wedbush in a report released on Thursday, MarketBeat.com reports. They ...

Monte Rosa reported that one of its molecular glue degraders had seen a strong response in immune disorders, but another fell short of expectations.

Cash, cash equivalents, restricted cash, and marketable securities as of December 31, 2024, were $377 million, compared to cash, cash ...

Wedbush analyst Robert Driscoll maintained a Buy rating on Monte Rosa Therapeutics (GLUE – Research Report) today and set a price target of ...

Lifesci Capital assumed coverage on shares of Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) in a research report issued to clients and investors on Wednesday, Marketbeat reports. The ...

Monte Rosa Therapeutics (NASDAQ: GLUE) showcased a promising outlook during its Q4 2024 earnings call, highlighting a robust cash runway projected into 2028. The company maintains a strong ...

BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines ...

Q4 2024 Results Conference Call March 20, 2025 8:00 AM ET. Company Participants. Andrew Funderburk - Senior Vice President, Investor Re ...

Monte Rosa Therapeutics (NASDAQ: GLUE) showcased a promising outlook during its Q4 2024 earnings call, highlighting a robust cash runway projected into 2028. The company maintains a strong financial ...